Cogent Q2 net loss $44.1M, cash $350.9M, PEAK DCR 55%, FGFR2 candidate nominated

Cogent Biosciences, Inc.

2023-Q2 EPS reported -$1.14

Cash & equivalents $350.9M at June 30 (up from $220.3M on Mar 31); funded into 2026.
Net loss Q2 2023: $44.1M vs $34.9M Q2 2022; R&D $38.9M vs $29.5M.
Phase 3 PEAK lead-in data: 55% DCR; 100% DCR and 17% ORR in evaluable 2nd-line GIST patients.
Selected FGFR2 kinase inhibitor as first internally developed candidate; preclinical data planned for 2H2023.
Initial SUMMIT (NonAdvSM) and updated APEX (AdvSM) data expected in second half of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Cogent Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income $44.1 million.

Period: the second quarter ended June 30, 2023
Net income: $44.1 million
Result: reported results

Exact text from the filing

Net loss was $44.1 million for the second quarter of 2023

View on SEC.gov

Browse all earnings releases →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039389

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.